---
schema_version: "secwatch.filing_event.v1"
accession: "0001656472-21-000090"
form_type: "8-K"
ticker: "CRON"
cik: "0001656472"
company_name: "Cronos Group Inc."
filed_at: "2021-08-06T23:59:59+00:00"
generated_at: "2026-06-29T20:37:06.103518+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cronos Group Q2 net revenue $15.6M (+58% YoY); gross loss expands to $15.8M; invests $110M in PharmaCann

## Summary
- Net revenue $15.6M, up 58% YoY; ROW segment $13.4M (+74%) driven by Canada adult-use and Israel medical.
- Gross loss $15.8M (from $2.9M loss); inventory write-downs $12M; Adj EBITDA loss $49.8M.
- Strategic investment: option to acquire ~10.5% stake in PharmaCann for ~$110.4M, with commercial agreements.
- Amended Ginkgo Bioworks agreement; commenced commercial-scale CBG production in June 2021.
- Appointed Kendrick Ashton Jr. to Board; new Head of Regulatory, Global Head of Audit, VP Controller.

## SEC filing metadata
- accession: 0001656472-21-000090
- form_type: 8-K
- ticker: CRON
- cik: 0001656472
- company_name: Cronos Group Inc.
- filed_at: 2021-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1656472/000165647221000090/0001656472-21-000090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1656472/000165647221000090/cron-20210806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001656472-21-000090
- JSON: https://secwatch.observer/filing/0001656472-21-000090.json
- Plain text: https://secwatch.observer/filing/0001656472-21-000090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.